Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate Use of Opaganib in Patients With Severe COVID-19

Next Previous
Search
Trial Profile

Compassionate Use of Opaganib in Patients With Severe COVID-19

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opaganib (Primary)
  • Indications COVID 2019 infections
  • Focus Expanded access; Therapeutic Use
  • Sponsors RedHill Biopharma

    • Most Recent Events

    • 24 Jun 2020 According to a RedHill Biopharma media release, results from the study have been published in medRxiv.
    • 24 Jun 2020 Results (n=5) presented in a RedHill Biopharma media release.
    • 27 Apr 2020 Preliminary results (n=6) published in the RedHill Biopharma Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top